Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, and RNA modifications and cancer.
Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics
The landscape of N6-methyladenosine in localized primary prostate cancer
Development and Validation of a Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic Cancer
Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection
<scp><i>NTRK</i></scp> fusion positive colorectal cancer is a unique subset of <scp>CRC</scp> with high <scp>TMB</scp> and microsatellite instability
Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer
Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer
Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer
Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer
Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study
Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell‐free DNA fragmentomics
Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases
Comprehensive Next-Generation Sequencing Reveals Novel Predictive Biomarkers of Recurrence and Thoracic Toxicity Risks After Chemoradiation Therapy in Limited Stage Small Cell Lung Cancer
Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients
Comprehensive next‐generation profiling of clonal hematopoiesis in cancer patients using paired tumor‐blood sequencing for guiding personalized therapies
Wait-and-See Treatment Strategy Could be Considered for Lung Adenocarcinoma with Special Pleural Dissemination Lesions, and Low Genomic Instability Correlates with Better Survival
Identification of kinase domain duplications across diverse cancer types in Chinese population by comprehensive genomic profiling (CGP).
Incidence of mutated DNA damage response pathway and clinically actionable alterations in Chinese patients with unknown primary tumor revealed by comprehensive genomic profiling.
Molecular Biomarkers for Chemoradiotherapy Response in Unresectable Limited Stage Small Cell Lung Cancer
Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Genes associated with increased brain metastasis risk in non–small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non–small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036)
Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer
Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA
Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI–Treated Non–Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy
Wait-and-See Treatment Strategy and Genomic Alternations Associated with Progression in Lung Adenocarcinoma with Pleural Dissemination
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients